Rhythm Pharmaceuticals IPO

10/4/2017

IPO

$119,850,000

We intend to use the net proceeds from this offering, together with our existing cash resources, as follows: approximately $17 million to fund the development and manufacturing of setmelanotide through completion of our Phase 3 clinical trials and subsequent NDA submissions with the FDA for the treatment of POMC deficiency obesity and LepR deficiency obesity; approximately $14 million for the development of setmelanotide through completion of our Phase 2 proof of concept clinical trials for Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity and POMC epigenetic disorders, as well as the initiation of our Phase 3 clinical trial for Bardet-Biedl syndrome; approximately $16 million for initiatives to expand the diagnosis of genetic obesity, including research and scientific exchange related to our ongoing genotyping and genetic epidemiology studies; approximately $38 million for preparation for commercialization of setmelanotide; and the remainder for general wor

Publicly-held

Biopharmaceutical

222 Berkeley St. 12th Floor
Boston, MA 02116
USA

Rhythm (NASDAQ: RYTM) is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases.